Avara to Buy Solid Dosage Production Site from AstraZenecaAvara to Buy Solid Dosage Production Site from AstraZeneca
October 6, 2017
Contract development and manufacturing organization Avara Pharmaceutical Services entered into an agreement to acquire AstraZeneca’s solid dosage manufacturing site and distribution facility in Reims, France, a press release announced Friday.
“This key acquisition is another important component of our strategic plan that further expands our services,” said Avara chairman and chief executive officer Timothy C. Tyson in a statement.
Providing API formulation and manufacturing and small molecule drug manufacturing, packaging, and distribution, the company currently uses a variety of technologies in production like granulation, coating, blending, encapsulation, and tablet and capsule drying.
Following the acquisition, the company will have eight total sites within its global network, including its Norwalk, CT headquarters.
“With rapid expansion and integration set for 2017-2018, we continue, with great confidence, to build a pharmaceutical services company with complimentary offerings in key regions to serve the rapidly growing market,” said Tyson. “Each site has significant professional experience, state of the art capability, and a long history of delivering high-quality pharmaceuticals to meet or exceed customer expectations and regulatory requirements in every major market in the world.”
For more news headlines, articles, and equipment reviews, visit our Equipment Zones
You May Also Like
1 Injured in Explosion at Industrial Adhesives & Coatings PlantDec 01, 2023
End-of-Year Chemical Industry OutlookDec 01, 2023
Post to Close Cereal Manufacturing FacilityDec 01, 2023
Child Labor Lawsuit Targets Major Food CompaniesDec 01, 2023